https://doi.org/10.55788/98551b4e
Bristol Myers gained the drug, approved last year for treating multiple sclerosis patients, in 2019 through its $74 billion buyout of Celgene.
Zeposia last year June met the main goals of a late-stage study, showing patients who took it achieved clinical remission of ulcerative colitis when compared to placebo. (https://reut.rs/2SA6RFe)
Cowen analyst Steve Scala, in a note on May 23, estimated Zeposia sales of $150 million in 2021, $400 million in 2022 and $1 billion in 2025.
Zeposia will compete with Takeda Pharmaceutical Co's drug Entyvio, which was approved in 2014 by the FDA for ulcerative colitis.
The European Medicines Agency is currently reviewing the marketing application for Zeposia to treat ulcerative colitis. A decision from the agency is expected in the second half of 2021, Bristol Myers said.
By Reuters Staff
Posted on
Previous Article
« Supplementary valve implantation during TAVR tied to worse outcomes Next Article
AstraZeneca drug Tagrisso gets EU nod for early lung cancer treatment »
« Supplementary valve implantation during TAVR tied to worse outcomes Next Article
AstraZeneca drug Tagrisso gets EU nod for early lung cancer treatment »
Related Articles
April 14, 2020
Possible new treatment targets in IBD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy